US FDA panel to vote on data, risk profile of Lilly Alzheimer’s drug

(Reuters) – A panel of outside experts to the U.S. health regulator will vote on Monday on whether data for Eli Lilly’s experimental treatment, donanemab, shows it is effective for treating patients with early Alzheimer’s disease.

The panel will also vote on whether benefits of the treatment outweigh its risks, according to documents published on the agency’s website.

Its recommendations are non-binding but typically followed by the U.S. Food and Drug Administration.

(Reporting by Bhanvi Satija in Bengaluru, Deena Beasley and Julie Steenhuysen; Editing by Bill Berkrot and Arun Koyyur)